Related Experiment Video

Updated: Sep 13, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Rewriting androgen-targeted therapy resistance with non-coding RNAs in prostate cancer treatment

Chamikara Liyanage1, Judith Clements2, Jyotsna Batra3

  • 1School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia; Cancer Program, The Centre for Genomics and Personalised Health and ARC Training Centre for Cell and Tissue Engineering Technologies (CTET), Queensland University of Technology, Brisbane, QLD 4059, Australia; Translational Research Institute, Queensland University of Technology, Woolloongabba, QLD 4102, Australia.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|July 30, 2025
PubMed

Insights

Non-coding RNAs (ncRNAs) are key regulators in prostate cancer, driving resistance to androgen-targeted therapy. Understanding ncRNA mechanisms offers new hope for biomarkers and treatments for advanced prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Prostate cancer is a leading cancer in men, often developing resistance to standard androgen-targeted therapy.
  • Metastatic castration-resistant prostate cancer (mCRPC) arises from adaptive resistance mechanisms.
  • Non-coding RNAs (ncRNAs), once overlooked, are now recognized as critical gene regulators.

Purpose of the Study:

  • To review ncRNA-mediated molecular mechanisms driving resistance to androgen-targeted therapy in prostate cancer.
  • To explore the potential of ncRNAs as biomarkers for prostate cancer progression.
  • To discuss ncRNAs as therapeutic targets to overcome treatment resistance.

Main Methods:

  • Literature review of studies on ncRNAs in prostate cancer.
  • Analysis of molecular pathways regulated by ncRNAs in therapy resistance.
  • Synthesis of current research on ncRNA clinical applications.

Main Results:

  • ncRNAs play a crucial role in prostate cancer development and progression.
  • ncRNAs can rewire oncogenic and tumor suppressor signaling pathways, contributing to therapy resistance.
  • Specific ncRNAs are implicated in the transition to castration-resistant prostate cancer.

Conclusions:

  • ncRNAs are indispensable regulators in prostate cancer, particularly in the context of treatment resistance.
  • ncRNAs hold significant promise as diagnostic biomarkers and therapeutic targets for advanced prostate cancer.
  • Targeting ncRNAs may offer novel strategies to circumvent resistance and improve patient outcomes.
Keywords:
androgen receptorandrogen-targeted therapycastration-resistant prostate cancernon-coding RNAprostate cancer

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.3K

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K